No One-Trick Pony: Alexion’s Evolution Into A Multi-Asset Drug Company
Executive Summary
Alexion has been recognized mainly as the marketer of Soliris since 2007, but in just eight weeks the rare disease specialist added two new drugs to its commercial portfolio. Management also laid out an impressive early- to mid-stage pipeline during its first-ever investor day, suggesting the company is well positioned for long-term growth.
You may also be interested in...
Alexion CEO Hantson Tasked With Kicking Growth Momentum Into Gear
The rare disease specialist’s new CEO is former Baxalta CEO Ludwig Hantson, who takes over the helm immediately after a leadership shakeup coinciding with an audit investigation.
Alexion Hunts For A CEO While Investors Await Investigation Details
CEO David Hallal and CFO Vikas Sinha have both left the company amid an audit investigation, while the company said it will file a delayed 10-Q in January or earlier.
Alexion’s Son of Soliris Aims To Takes Dosing Right Down
Alexion is setting its sights on eight-weekly dosing for its follow-up candidate to its blockbuster Soliris, testing this schedule in its new Phase III trial in patients with paroxysmal nocturnal hemoglobinuria (PNH), based on new Phase I/II data just presented at the ASH meeting in San Diego.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: